article

European Pharmaceutical Review Issue 4 2019

Posted: 28 August 2019 | | 1 comment

This issue includes an investigation into the potential for continuous production lines in biopharma, information on new guidance released by China on their regulatory processes and an assessment of the FMD to improve the drug supply chain. Also within the issue are articles on nanomedicine development, monoclonal antibodies and pharmaceutical imaging.

European Pharmaceutical Review Issue 4 2019

Included in this issue:

  • REGULATORY INSIGHT
    China and the evolving regulatory landscape
    Megha Baruah, Freyr
  • FORMULATION, DEVELOPMENT & DELIVERY
    Hitting the target – refining anticancer nanomedicine development
    Mahfoozur Rahman, Sam Higginbottom University of Agriculture and Sarwar Beg, Jamia Hamdard (Hamdard University)
  • BIOPROCESSING & BIOPRODUCTION
    On the edge of glory: how close are we to fully automated continuous biopharma production?
    Loe Cameron, Pall Corporation
  • MANUFACTURING, PACKAGING & LOGISTICS
    How tablet formulation can impact production
    Rob Blanchard, I Holland
  • QA/QC & ANALYTICAL TECHNIQUES ICH
    Q10 knowledge management
    Christian Rack

The rest of this content is restricted - login or subscribe free to access

EPR Issue 5 front coverThank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.

Why subscribe? Join our growing community of thousands of industry professionals and gain access to:

  • bi-monthly issues in print and/or digital format
  • case studies, whitepapers, webinars and industry-leading content
  • breaking news and features
  • our extensive online archive of thousands of articles and years of past issues
  • ...And it's all free!

Click here to Subscribe today Login here

 

One response to “European Pharmaceutical Review Issue 4 2019”

  1. sandeep vishnani says:

    Good updates

Leave a Reply

Your email address will not be published. Required fields are marked *